IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene PAX5 Ensembl ENSG00000196092 Chromosome 9 Start 36828539 End 37024476
Description Paired box protein Pax-5 (B-cell-specific transcription factor)(BSAP) [Source:UniProtKB/Swiss-Prot;Acc:Q02548]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 8619
     Entrez Gene : 5079
     UCSC : uc003zzo.1
     GeneCards : 8619
     RefSeq : NM_016734
     CCDS : CCDS6607.1
     Uniprot : Q02548
     Interpro : Q02548
     OMIM : 167414
     GeneTests : PAX5
     CGAP : PAX5
     PMID : 1516825

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  34620_at  0.13  3.53e-1  4.60e-1  0.40  9.48e-2  1.57e-1
 HG_U133A  206802_at  0.20  9.49e-2  1.25e-1  0.00  9.96e-1  9.97e-1
 HG_U133_Plus2  206802_at  0.11  4.59e-1  5.48e-1  0.07  6.89e-1  7.35e-1
 Stanford  22475  0.23  5.64e-1  7.31e-1  0.28  4.79e-1  7.00e-1
 Agilent_HS_21.6K  12086  0.05  7.31e-3  3.61e-2  0.06  1.33e-3  6.88e-3

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  206802_at  0.75  6.59e-2  7.28e-1  -0.10  7.12e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 34620_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 206802_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 206802_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 22475    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 12086    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
bsap multiple myeloma Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. 11841448 Human
bsap multiple myeloma Using reverse transcription polymerase chain reaction, we studied the expression of five TFs (octamer binding factor oct-2, ets family members PU.1 and Spi-B, pax gene family member BSAP, and Blimp-1) in (1) human cell lines with a plasma cell phenotype, 11841448 Human
bsap plasma-cell leukaemia (pcl) Using reverse transcription polymerase chain reaction, we studied the expression of five TFs (octamer binding factor oct-2, ets family members PU.1 and Spi-B, pax gene family member BSAP, and Blimp-1) in (1) human cell lines with a plasma cell phenotype, 11841448 Human
pax5 myeloma In the Pax5-expressing cell lines 38B9 (pre-B) and 2PK-3 (mature B), all CpG sites in TATA-containing upstream promoter were unmethylated, whereas these sites were completely methylated in myeloma cell lines FO and Sp-2/0, which do not express Pax5. 12044782 Human
bsap tumour In contrast to their non-plasmacytoid counterparts, the 'plasmacytoid' EMZL tumour cells were negative for the B cell markers CD20 and BSAP, and demonstrated heterogeneous positivity for the markers MUM1, Vs38c, CD38 and CD138. 12115879 Human
bsap leukemias Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. 12360049 Human
bsap b-cell non-hodgkin lymphomas Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. 12360049 Human
pax5 multiple myeloma Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. 12453881 Human
pax5 primary central-nervous-system lymphomas We have addressed whether aberrant ongoing hypermutation can be detected in the proto-oncogenes PIM1, c-MYC, RhoH/TTF, PAX5, and the tumor-suppressor gene CD95 in primary central nervous system lymphomas (PCNSLs) derived from immunocompetent HIV-negative 14592832 Human
pax5 tumors Nine of 10 PCNSLs analyzed harbored somatic mutations in the PIM1, c-MYC, RhoH/TTF, and PAX5 genes, but not in the CD95 gene, with 8 tumors carrying alterations in at least 2 of these genes. 14592832 Human
bsap chronic lymphocytic leukemia We explored the involvement of BSAP in the growth regulation of malignant B-1 cells derived from the NZB murine model of human chronic lymphocytic leukemia. 11315509 Human
pax5 acute lymphoblastic leukemia The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. 11406533 Human
pax5 tumour Overall, the results indicate a key role for a tumour suppressor gene(s) encoded in an approximately 3 cM segment on proximal chromosome 4 and provide an experimental basis for the further investigation of the functional role of candidate genes which incl 11433528 Human
pax5 large-cell lymphomas Here we report that an aberrant hypermutation activity targets multiple loci, including the proto-oncogenes PIM1, MYC, RhoH/TTF (ARHH) and PAX5, in more than 50% of diffuse large-cell lymphomas (DLCLs), which are tumours derived from germinal centres. 11460166 Human
pax5 tumours Here we report that an aberrant hypermutation activity targets multiple loci, including the proto-oncogenes PIM1, MYC, RhoH/TTF (ARHH) and PAX5, in more than 50% of diffuse large-cell lymphomas (DLCLs), which are tumours derived from germinal centres. 11460166 Human
pax5 tumors We have investigated whether Pax5 can induce tumors in the developing mouse brain. 11477548 Human
pax5 tumors The majority cases of B-cell tumors expressed considerable levels of PAX5/BSAP irrespective of whether they exhibited t(9;14)(p13;q32), suggesting that quantitative differences in expression level alone may not account for the development of this particul 10784387 Human
bsap tumors The majority cases of B-cell tumors expressed considerable levels of PAX5/BSAP irrespective of whether they exhibited t(9;14)(p13;q32), suggesting that quantitative differences in expression level alone may not account for the development of this particul 10784387 Human
bsap b-cell lymphomas Both in normal lymphoid tissue and non-Hodgkin lymphomas, BSAP transcripts and protein were almost exclusively found in B cells and B-cell lymphomas (40 cases), but were absent from the tumor cells of T-cell neoplasms (41 cases), including 19 cases of ana 10556196 Human
bsap anaplastic large-cell lymphoma Both in normal lymphoid tissue and non-Hodgkin lymphomas, BSAP transcripts and protein were almost exclusively found in B cells and B-cell lymphomas (40 cases), but were absent from the tumor cells of T-cell neoplasms (41 cases), including 19 cases of ana 10556196 Human
bsap neoplasms Both in normal lymphoid tissue and non-Hodgkin lymphomas, BSAP transcripts and protein were almost exclusively found in B cells and B-cell lymphomas (40 cases), but were absent from the tumor cells of T-cell neoplasms (41 cases), including 19 cases of ana 10556196 Human
bsap tumor Both in normal lymphoid tissue and non-Hodgkin lymphomas, BSAP transcripts and protein were almost exclusively found in B cells and B-cell lymphomas (40 cases), but were absent from the tumor cells of T-cell neoplasms (41 cases), including 19 cases of ana 10556196 Human
bsap non-hodgkin lymphomas Both in normal lymphoid tissue and non-Hodgkin lymphomas, BSAP transcripts and protein were almost exclusively found in B cells and B-cell lymphomas (40 cases), but were absent from the tumor cells of T-cell neoplasms (41 cases), including 19 cases of ana 10556196 Human
bsap anaplastic large-cell lymphoma BSAP expression in HRS cells provides further strong evidence for a frequent B-cell origin of cHD and helps distinguish this disease from anaplastic large cell lymphoma of T- and null-cell type. 10556196 Human
bsap retinoblastoma The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. 10197586 Human
bsap lymphoma Pax-5 codes for the transcription factor BSAP, which plays an important role in midbrain patterning, B cell development, and lymphoma formation. 10197586 Human
pax5 lymphoplasmacytic lymphomas Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). 15116325 Human
pax5 lymphoplasmacytic lymphoma A t(9;14)(p13;q32) involving the PAX5 and IGH genes has been described in association with lymphoplasmacytic lymphoma. 15116325 Human
bsap lymphoplasmacytic lymphoma Recently, we found that t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytic lymphoma (LPL) juxtaposes PAX-5 gene encoding for an essential transcription factor (BSAP: B-cell specific activator protein) for B-cell proliferation and 10350329 Human
pax5 transitional cell carcinoma The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. 10368252 Human
pax5 tumours There was a significantly higher proportion of PAX5 expression in malignant than in benign urothelium (P=0.02, Fisher's exact test); nine of 12 pTa tumours (mucosa-confined), seven of eight pT1 (invading lamina propria) and eight of nine pT2 (invadin 10368252 Human
pax5 tumours A higher proportion of tumours with increasing de-differentiation expressed PAX5, which correlates well with the expression pattern of PAX5 in development. 10368252 Human
pax5 tumours In well-differentiated tumours (grade 1), half expressed PAX5, compared with 84% of moderately to poorly differentiated tumours (grades 2/3). 10368252 Human
pax5 myeloma Pax5 gene expression was detected in B cell lines but not in myeloma cell lines. 9486401 Human
bsap b-cell lymphomas Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. 9694719 Human
bsap non-hodgkin's lymphoma Despite its known involvement in a rare subtype of non-Hodgkin's lymphoma (NHL), a detailed examination of BSAP expression in NHL has not been previously reported. 9694719 Human
bsap large b-cell lymphomas Eight of 12 (67%) marginal zone lymphoma cases showed negative or low BSAP levels, and 17 of 24 (71%) large B-cell lymphomas displayed moderate to strong expression. 9694719 Human
bsap marginal-zone lymphoma Eight of 12 (67%) marginal zone lymphoma cases showed negative or low BSAP levels, and 17 of 24 (71%) large B-cell lymphomas displayed moderate to strong expression. 9694719 Human
bsap tumor None of the 23 T- and null-cell lymphomas reacted with the BSAP antisera, whereas in Hodgkin's disease, 2 of 4 (50%) nodular lymphocytic predominance and 5 of 14 (36%) classical cases showed weak nuclear or nucleolar BSAP reactions in a fraction of t 9694719 Human
bsap lymphomas None of the 23 T- and null-cell lymphomas reacted with the BSAP antisera, whereas in Hodgkin's disease, 2 of 4 (50%) nodular lymphocytic predominance and 5 of 14 (36%) classical cases showed weak nuclear or nucleolar BSAP reactions in a fraction of t 9694719 Human
bsap lymphomas We conclude that BSAP expression is largely restricted to lymphomas of B-cell lineage and that BSAP expression varies in B-cell subsets and subtypes of B-cell NHL. 9694719 Human
bsap large-cell lymphomas The high levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, may be a consequence of deregulated gene expression and suggest a possible involvement of PAX-5 in certain B-cell malignancies. 9694719 Human
bsap follicular lymphomas The high levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, may be a consequence of deregulated gene expression and suggest a possible involvement of PAX-5 in certain B-cell malignancies. 9694719 Human
pax5 non-hodgkin's lymphoma Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. 9722295 Human
bsap non-hodgkin's lymphoma Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. 9722295 Human
pax5 tumour Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. 9722295 Human
bsap tumour Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. 9722295 Human
pax5 non-hodgkin's lymphoma A recurring translocation t(9;14)(p13;q32) in non-Hodgkin's lymphoma moves the PAX5 on 9p13 within close proximity of the immunoglobulin heavy chain gene (IGH). 9722295 Human
pax5 tumour We analysed PAX5/BSAP expression by Northern and Western blotting in a panel of haematological tumour cell lines with other chromosome abnormalities in comparison with that of KIS-1. 9722295 Human
bsap tumour We analysed PAX5/BSAP expression by Northern and Western blotting in a panel of haematological tumour cell lines with other chromosome abnormalities in comparison with that of KIS-1. 9722295 Human
pax5 diffuse large b-cell lymphoma However, a diffuse large B-cell lymphoma cell line and an acute B-lymphoid/myeloid leukaemia cell line expressed the PAX5/BSAP at levels comparable with KIS-1. 9722295 Human
bsap diffuse large b-cell lymphoma However, a diffuse large B-cell lymphoma cell line and an acute B-lymphoid/myeloid leukaemia cell line expressed the PAX5/BSAP at levels comparable with KIS-1. 9722295 Human
pax5 leukaemia However, a diffuse large B-cell lymphoma cell line and an acute B-lymphoid/myeloid leukaemia cell line expressed the PAX5/BSAP at levels comparable with KIS-1. 9722295 Human
bsap leukaemia However, a diffuse large B-cell lymphoma cell line and an acute B-lymphoid/myeloid leukaemia cell line expressed the PAX5/BSAP at levels comparable with KIS-1. 9722295 Human
pax5 neoplasms PAX5 transcripts were readily detectable in clinical materials with a wide variety of B-cell neoplasms by reverse transcriptase-mediated polymerase chain reaction (PCR). 9722295 Human
pax5 tumour Thus, PAX5/BSAP activation in haematological tumour cells is not necessarily associated with t(9;14). 9722295 Human
bsap tumour Thus, PAX5/BSAP activation in haematological tumour cells is not necessarily associated with t(9;14). 9722295 Human
bsap plasmacytoma In addition, cotransfections with reporter constructs plus different amounts of expression plasmids for BSAP showed that CD72 promoter activity was up-regulated by BSAP in plasmacytoma cells and T cells in a dose-dependent manner. 9794407 Human
bsap lymphomas In both lymphomas, the J-chain gene, which is thought to be under negative control by BSAP, was not expressed, whereas transcription of the putative target gene p53 was unaffected by PAX-5 overexpression. 9808580 Human
bsap lymphoma The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. 14608905 Human
pax5 lymphoplasmacytoid lymphoma The t(9;14) translocation associated with the B cell tumor lymphoplasmacytoid lymphoma juxtaposes the PAX5 gene into the vicinity of the IGH locus to deregulate PAX5 expression. 9570138 Human
pax5 cell tumor The t(9;14) translocation associated with the B cell tumor lymphoplasmacytoid lymphoma juxtaposes the PAX5 gene into the vicinity of the IGH locus to deregulate PAX5 expression. 9570138 Human
bsap myeloma To clarify the meaning of loss of CD19 antigen on myeloma cells, we first compared the expression of CD19 and Pax-5 genes among B cells, normal plasma cells, myeloma cell lines, and primary myeloma cells, because the Pax-5 gene was reported to encode the 8639790 Human
pax5 superficial bladder carcinoma The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. 14577491 Human
pax5 bladder transitional cell carcinoma OBJECTIVES: The expression pattern of PAX5 in the tissue of superficial bladder transitional cell carcinoma (TCC), its prognostic value and its correlation with p53 immunohistochemistry and p53 mutation analysis were evaluated. 14577491 Human
pax5 benign prostatic hyperplasia As the control group for the evaluation of the PAX5 expression served 8 men with benign prostatic hyperplasia. 14577491 Human
bsap myeloma Virtually all B-cell lines, with the exception of some myeloma cell lines, are positive for BSAP, which is the transcription factor for promoters for several B-cell markers, including VpreB1, lambda 5, CD19, and CD20. 8780159 Human
pax5 tumor In the desmoplastic variant of medulloblastoma, PAX5 expression was restricted to the reticulin-producing proliferating tumor areas containing undifferentiated cells; PAX5 was not expressed in the reticulin-free nonproliferating islands undergoing neurona 7777574 Human
pax5 desmoplastic medulloblastoma These data suggest that deregulated expression of PAX5 correlates positively with cell proliferation and inversely with neuronal differentiation in desmoplastic medulloblastoma. 7777574 Human
pax5 tumors Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. 12406913 Human
pax5 non-hodgkin lymphomas Both Pax5 and c-Myc are implicated in the pathogenesis of non-Hodgkin lymphomas. 12406913 Human
pax5 lymphomas All Myc-induced lymphomas invariably maintained expression of Pax5, which is thought to be incompatible with terminal differentiation. 12406913 Human
pax5 tumors Remarkably, pooled cells rapidly re-expressed Pax5 and formed tumors of relatively mature lymphoid phenotype, with surface immunoglobulins being abundantly expressed. 12406913 Human
pax5 cancers Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. 12907641 Human
pax5 cancer Recent studies have demonstrated the importance of PAX5 gene alterations in human cancer. 12907641 Human
pax5 glioblastoma The epidermal growth factor receptor was highly expressed in glioblastoma multiform tumors in areas which were also highly PAX5 positive. 9815975 Human
pax5 tumors The epidermal growth factor receptor was highly expressed in glioblastoma multiform tumors in areas which were also highly PAX5 positive. 9815975 Human
bsap lymphoma Antisense-induced BSAP suppression was associated with a striking reduction in LPS-induced proliferation of splenic B cells and in the spontaneous proliferation of B lymphoma cells (CH12.LX), but the antisense oligonucleotide had virtually no effect on pr 7511679 Human
bsap b lymphoma Antisense-induced BSAP suppression was associated with a striking reduction in LPS-induced proliferation of splenic B cells and in the spontaneous proliferation of B lymphoma cells (CH12.LX), but the antisense oligonucleotide had virtually no effect on pr 7511679 Human
bsap plasmacytoma To assess the possible functional role of these BSAP binding sites in the 3' alpha enhancer, we transiently transfected a construct containing a 314-bp 3' alpha enhancer fragment upstream of a luciferase reporter gene in MOPC-315 cells, a plasma 8021508 Human
bsap b lymphoma Conversely, in the mature B lymphoma cell line CH12.LX, a cell line that expresses BSAP and has a less active 3' alpha enhancer, selective BSAP down-regulation by an antisense phosphorothioate oligonucleotide was sufficient to considerably up-regulat 8021508 Human
bsap hodgkin's disease None of the 23 T- and null-cell lymphomas reacted with the BSAP antisera, whereas in Hodgkin's disease, 2 of 4 (50%) nodular lymphocytic predominance and 5 of 14 (36%) classical cases showed weak nuclear or nucleolar BSAP reactions in a fraction of t 9694719 Human
bsap b-cell non-hodgkin's lymphoma Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. 9722295 Human
bsap t-cell neoplasms Both in normal lymphoid tissue and non-Hodgkin lymphomas, BSAP transcripts and protein were almost exclusively found in B cells and B-cell lymphomas (40 cases), but were absent from the tumor cells of T-cell neoplasms (41 cases), including 19 cases of ana 10556196 Human
bsap malignancy These data suggest a correlation between BSAP and the development of B-1 malignancy, perhaps through the regulation of cell-cycle progression. 11315509 Human
bsap mature b-cell non-hodgkin lymphomas Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. 12360049 Human
bsap classical hodgkin's lymphoma [Expression and significance of B-cell-specific activator protein of H/RS cell in classical Hodgkin's Lymphoma] OBJECTIVE: To explore the expression of B-cell-specific activator protein (BSAP) of H/RS cell in classical Hodgkin's lymphoma (cHL). 12609061 Human
bsap b-cell lymphoma Nine samples of lymph node of reactive hyperplasia, 10 samples of B-cell lymphoma, and 10 samples of T-cell lymphoma were also detected as BSAP controls. 12609061 Human
bsap t-cell lymphoma Nine samples of lymph node of reactive hyperplasia, 10 samples of B-cell lymphoma, and 10 samples of T-cell lymphoma were also detected as BSAP controls. 12609061 Human
bsap hyperplasia Nine samples of lymph node of reactive hyperplasia, 10 samples of B-cell lymphoma, and 10 samples of T-cell lymphoma were also detected as BSAP controls. 12609061 Human
bsap hyperplasia Almost all B cells of lymph node reactive hyperplasia were BSAP positive. 12609061 Human
bsap b-cell lymphoma All malignant cells in B-cell lymphoma were BSAP positive, while all malignant cells in T-cell lymphoma were BSAP negative. 12609061 Human
bsap t-cell lymphoma All malignant cells in B-cell lymphoma were BSAP positive, while all malignant cells in T-cell lymphoma were BSAP negative. 12609061 Human
bsap hodgkin's disease CONCLUSION: The frequent expression of BSAP in H/RS cells of classical Hodgkin's disease provides further evidence for its B-cell origin and helps to identify H/RS cells. 12609061 Human
bsap anaplastic large-cell lymphoma The expression of BSAP in H/RS cells can be used to distinguish HL from anaplastic large cell lymphoma (ALCL). 12609061 Human
bsap hl The expression of BSAP in H/RS cells can be used to distinguish HL from anaplastic large cell lymphoma (ALCL). 12609061 Human
bsap alcl The expression of BSAP in H/RS cells can be used to distinguish HL from anaplastic large cell lymphoma (ALCL). 12609061 Human
bsap lrchl Furthermore, they demonstrate that LRCHL is distinct from NLPHL and that it is closely related to the mixed cellularity CHL (MCHL) in respect of BSAP, BOB.1, and Oct2 expression. 12647220 Human
bsap nlphl Furthermore, they demonstrate that LRCHL is distinct from NLPHL and that it is closely related to the mixed cellularity CHL (MCHL) in respect of BSAP, BOB.1, and Oct2 expression. 12647220 Human
bsap mchl Furthermore, they demonstrate that LRCHL is distinct from NLPHL and that it is closely related to the mixed cellularity CHL (MCHL) in respect of BSAP, BOB.1, and Oct2 expression. 12647220 Human
bsap hodgkin lymphoma The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. 14608905 Human
bsap classical hodgkin lymphoma (chl) METHODS: Immunohistochemical method was used to detect the expression of B-cell-specific activator protein (BSAP) and CD(20) in 33 paraffin-embedded tissues of classical Hodgkin lymphoma (cHL). 14690578 Human
bsap t-cell lymphomas BSAP and CD(20) were positive in almost all B cells of lymph node reactive hyperplasia and malignant cells in B-cell lymphomas while were negative in all malignant cells of T-cell lymphomas. 14690578 Human
bsap b-cell lymphomas BSAP and CD(20) were positive in almost all B cells of lymph node reactive hyperplasia and malignant cells in B-cell lymphomas while were negative in all malignant cells of T-cell lymphomas. 14690578 Human
bsap hyperplasia BSAP and CD(20) were positive in almost all B cells of lymph node reactive hyperplasia and malignant cells in B-cell lymphomas while were negative in all malignant cells of T-cell lymphomas. 14690578 Human
bsap hodgkin's lymphoma METHOD: IgH gene rearrangement was detected in paffin-embedded tissues from 33 patients with Hodgkin's lymphoma and a further analysis of the gene rearrangement was conducted in 6 of the positive cases identified after immunostaining of the sections 15041542 Human
bsap myeloma To investigate PAX5 gene expression and its protein product, B-cell-specific activator protein (BSAP), in a subgroup of multiple myeloma characterized by CD20 expression, we studied PAX5/BSAP by immunohistochemistry in 25 cases of myeloma, all expressing 15195108 Human
bsap multiple myeloma To investigate PAX5 gene expression and its protein product, B-cell-specific activator protein (BSAP), in a subgroup of multiple myeloma characterized by CD20 expression, we studied PAX5/BSAP by immunohistochemistry in 25 cases of myeloma, all expressing 15195108 Human
bsap myelomas PAX5 mRNA levels correlated inversely with that of PRDM1 in both CD20-positive and CD20-negative myelomas and failed to predict the expression levels of PAX5/BSAP, suggesting that detected PAX5/BSAP likely represents remnant of earlier stage of developmen 15195108 Human
bsap myelomas We conclude that CD20-positive myelomas expressing PAX5/BSAP can present as a diagnostic pitfall mimicking B-cell neoplasms with plasmacytoid differentiation. 15195108 Human
bsap neoplasms We conclude that CD20-positive myelomas expressing PAX5/BSAP can present as a diagnostic pitfall mimicking B-cell neoplasms with plasmacytoid differentiation. 15195108 Human
bsap ca METHODS: Serum calcium (Ca), phosphate, bone-specific alkaline phosphatase (BSAP) and 25-hydroxyvitamin D3 (25-OH D) were measured at baseline and 12 months after LRYGBP. 15479594 Human
bsap chronic lymphocytic leukemia Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. 15561888 Human
pax-5 acute lymphoblastic leukemia This transactivation domain was found to be inactivated by a naturally occurring frameshift mutation in one PAX-5 allele of the acute lymphoblastic leukemia cell line REH. 8617244 Human
pax-5 myeloma Altered expression of Pax-5 gene in human myeloma cells. 8639790 Human
pax-5 myeloma To clarify the meaning of loss of CD19 antigen on myeloma cells, we first compared the expression of CD19 and Pax-5 genes among B cells, normal plasma cells, myeloma cell lines, and primary myeloma cells, because the Pax-5 gene was reported to encode the 8639790 Human
pax-5 myeloma Neither CD19 nor Pax-5 mRNA could be detected in those primary myeloma cells and cell lines, whereas normal plasma cells did express both CD19 and Pax-5 mRNA. 8639790 Human
pax-5 myeloma Therefore, these data suggest that the altered expression of Pax-5, but not E2A or Id, is responsible for the loss of CD19 expression in human myeloma cells, although the underlying mechanism of the altered Pax-5 gene expression remains to be clarified. 8639790 Human
pax-5 large-cell lymphoma Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. 8650231 Human
pax-5 large-cell lymphomas The human PAX-5 gene is located on chromosome 9 in region p13, which is involved in t(9;14)(pl3;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype and in derived large-cell lymphomas. 8650231 Human
pax-5 small-lymphocytic lymphomas The human PAX-5 gene is located on chromosome 9 in region p13, which is involved in t(9;14)(pl3;q32) translocations recurring in small lymphocytic lymphomas of the plasmacytoid subtype and in derived large-cell lymphomas. 8650231 Human
pax-5 small-lymphocytic lymphomas These data suggest that deregulation of PAX-5 gene transcription by the t(9;14)(pl3;q32) translocation contributes to the pathogenesis of small lymphocytic lymphomas with plasmacytoid differentiation. 8650231 Human
pax-5 myeloma The expression of Pax-5 gene is altered in human myeloma cells (malignant plasma cells). 8912652 Human
pax-5 lymphoplasmacytoid lymphoma The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. 8943844 Human
pax-5 large-cell lymphomas The high levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, may be a consequence of deregulated gene expression and suggest a possible involvement of PAX-5 in certain B-cell malignancies. 9694719 Human
pax-5 follicular lymphomas The high levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, may be a consequence of deregulated gene expression and suggest a possible involvement of PAX-5 in certain B-cell malignancies. 9694719 Human
pax-5 marginal-zone lymphoma Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. 9808580 Human
pax-5 small lymphocytic lymphoma with plasmacytoid differentiation PAX-5 (on 9p13) has been involved together with the immunoglobulin heavy-chain (IgH) gene (on 14q32) in the recurring t(9;14)(p13;q32) translocation that is characteristic of small lymphocytic lymphoma with plasmacytoid differentiation. 9808580 Human
pax-5 b-cell lymphoma For comparison we have analyzed PAX-5 expression in another B-cell lymphoma, KIS-1, indicating that transcription from the distal PAX-5 promoter was increased in this tumor in agreement with the previously characterized translocation of the immunoglobulin 9808580 Human
pax-5 tumor For comparison we have analyzed PAX-5 expression in another B-cell lymphoma, KIS-1, indicating that transcription from the distal PAX-5 promoter was increased in this tumor in agreement with the previously characterized translocation of the immunoglobulin 9808580 Human
pax-5 lymphomas In both lymphomas, the J-chain gene, which is thought to be under negative control by BSAP, was not expressed, whereas transcription of the putative target gene p53 was unaffected by PAX-5 overexpression. 9808580 Human
pax-5 lymphoma Together these data indicate that the t(9;14)(p13;q32) translocation contributes to lymphoma formation as a regulatory mutation that leads to increased PAX-5 expression in late B-cell differentiation due to promoter replacement or enhancer insertion. 9808580 Human
pax-5 primary-effusion lymphoma Herpes virus type 8-negative primary effusion lymphoma associated with PAX-5 gene rearrangement and hepatitis C virus: a case report and review of the literature. 9850179 Human
pax-5 primary-effusion lymphoma (pel) At present, there is no case report of HHV8- primary effusion lymphoma (PEL) with t(9;14)(p13;q32) involving both PAX-5 and immunoglobulin heavy chain gene rearrangement, which is a rare translocation in B-cell non-Hodgkin's lymphoma, in an HIV- pati 9850179 Human
pax-5 b-cell non-hodgkin's lymphoma At present, there is no case report of HHV8- primary effusion lymphoma (PEL) with t(9;14)(p13;q32) involving both PAX-5 and immunoglobulin heavy chain gene rearrangement, which is a rare translocation in B-cell non-Hodgkin's lymphoma, in an HIV- pati 9850179 Human
pax-5 pel This case is the first report of an HHV8- PEL with t(9;14) involving a PAX-5 gene rearrangement in an HIV-seronegative patient. 9850179 Human
pax-5 primary-effusion lymphoma These findings suggest that there may be an additional subcategory of primary effusion lymphoma that is not associated with HHV8 nor c-MYC(R) but is pathogenetically associated with the PAX-5 gene or hepatitis C virus. 9850179 Human
pax-5 lymphoplasmacytoid lymphoma Lymphoplasmacytoid lymphoma carries t(9;14) (p13;q32) in approximately 50% of cases, leading to the deregulated expression of the PAX-5 gene. 10681729 Human
pax-5 myeloma [Pax-5 genes and CD19 molecules in human myeloma] 10879100 Human
pax-5 non-hodgkin's lymphoma t(9;14)(p13;q32) involving the PAX-5 gene: a unique subtype of 14q32 translocation in B cell non-Hodgkin's lymphoma. 10071452 Human
pax-5 retinoblastoma The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins. 10197586 Human
pax-5 lymphoma Pax-5 codes for the transcription factor BSAP, which plays an important role in midbrain patterning, B cell development, and lymphoma formation. 10197586 Human
pax-5 rb Both TBP and Rb were shown by coimmunoprecipitation experiments to directly associate with Pax-5 in vivo. 10197586 Human
pax-5 rb The conserved core domain of TBP and the pocket region as well as COOH-terminal sequences of Rb are required for interaction with the partial homeodomain of Pax-5 in in vitro binding assays. 10197586 Human
pax-5 rb Furthermore, Pax-5 was specifically bound only by the underphosphorylated form of Rb. 10197586 Human
pax-5 rb These data indicate that Pax-5 is able to contact the basal transcription machinery through the TBP-containing initiation factor TFIID, and that its activity can be controlled by the cell cycle-regulated association with Rb. 10197586 Human
pax-5 lymphoplasmacytic lymphoma Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). 10350329 Human
pax-5 lymphoplasmacytic lymphoma Recently, we found that t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytic lymphoma (LPL) juxtaposes PAX-5 gene encoding for an essential transcription factor (BSAP: B-cell specific activator protein) for B-cell proliferation and 10350329 Human
pax-5 diffuse large cell lymphoma (dlcl) Thus, an understanding of the PAX-5 gene's physiological role in B-cell development and the pathological role in tumorigenesis may lead to the optimal clinical treatment strategy for LPL and LPL-derived diffuse large cell lymphoma (DLCL). 10350329 Human
pax-5 retinoblastoma Dissociation of Pax-5 from KI and KII sites during kappa-chain gene rearrangement correlates with its association with the underphosphorylated form of retinoblastoma. 11359826 Human
pax-5 retinoblastoma During differentiation induced by removing IL-7, the underphosphorylated form of retinoblastoma preferentially associated with Pax-5, which caused dissociation of Pax-5 from KI and KII sites. 11359826 Human
pax-5 neoplasms The protein products of other genes activated by chromosomal rearrangement have a role as markers of either lineage (eg, PAX-5 [B-cell-specific activator protein] for B cells, including B-lymphoblastic neoplasms), or maturation stage (eg, BCL-6 for germin 11781220 Human
pax-5 lymphoma In addition, this PEL case harbored PAX-5 gene mutations, which have been recently demonstrated as a key feature of the proto-oncogene hypermutation process involved in the pathogenesis of some lymphoma types. 11975116 Human
pax-5 pel In addition, this PEL case harbored PAX-5 gene mutations, which have been recently demonstrated as a key feature of the proto-oncogene hypermutation process involved in the pathogenesis of some lymphoma types. 11975116 Human
pax-5 primary tumour Moreover, we demonstrate that PU.1 and PAX-5 are significantly down-regulated in HRS cells in pathological specimens from primary tumour tissues. 12118370 Human
pax-5 tumor The T cell-derived tumor cells displayed aberrant expression of the Pax-5 gene in all specimens. 12218070 Human
pax-5 leukemias Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. 12360049 Human
pax-5 mature b-cell non-hodgkin lymphomas Pax-5 protein (BSAP) was detected in all cases of precursor and mature B-cell non-Hodgkin lymphomas/leukemias. 12360049 Human
pax-5 hodgkin lymphomas In addition, in 97% of classic Hodgkin lymphomas, Reed-Sternberg cells expressed Pax-5. 12360049 Human
pax-5 diffuse large b-cell lymphomas However, Pax-5 was not detected in any of the multiple myelomas, solitary plasmacytomas, and 4% of diffuse large B-cell lymphomas. 12360049 Human
pax-5 solitary plasmacytomas However, Pax-5 was not detected in any of the multiple myelomas, solitary plasmacytomas, and 4% of diffuse large B-cell lymphomas. 12360049 Human
pax-5 multiple myelomas However, Pax-5 was not detected in any of the multiple myelomas, solitary plasmacytomas, and 4% of diffuse large B-cell lymphomas. 12360049 Human
pax-5 diffuse large b-cell lymphomas Among those diffuse large B-cell lymphomas not expressing Pax-5 were only those with terminal B-cell differentiation. 12360049 Human
pax-5 hodgkin lymphoma Even though there is an excellent correlation between CD20 and Pax-5 expression, anti-Pax-5 exceeds the specificity and sensitivity of L26 (anti-CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B ce 12360049 Human
pax-5 hl Because several genes down-regulated in HRS cells are positively regulated by the transcriptional activator Pax-5, which is expressed in most HRS cells, we studied HL cell lines for mutations in the Pax-5 gene. 12393731 Human
pax-5 plasmacytoma Here, we use a novel cell-based system to show that retrovirally expressed Pax-5 protein activates endogenous early B-cell-specific mb-1 genes in plasmacytoma cells, but only when the promoter is hypomethylated. 12612069 Human
pax-5 tumors In these tumors, the somatic hypermutation (SHM) process that normally targets immunoglobulin V (IgV) genes in B cells appears to misfire and causes mutations in the 5' sequences of multiple proto-oncogenes, including PIM-1, PAX-5, RhoH/TTF, and c-MY 12714522 Human
pax-5 tumor Nuclear antigens include cell cycle-associated proteins (such as cyclins, p16, Ki-67), nuclear enzymes (such as TdT), transcription factors (such as TTF-1, CDX-2, myogenin, PAX-5), tumor suppressor gene products (such as p53, p63, WT1, Rb), steroid hormon 15306932 Human
pax-5 rb Nuclear antigens include cell cycle-associated proteins (such as cyclins, p16, Ki-67), nuclear enzymes (such as TdT), transcription factors (such as TTF-1, CDX-2, myogenin, PAX-5), tumor suppressor gene products (such as p53, p63, WT1, Rb), steroid hormon 15306932 Human
pax-5 b-cell lymphoma The transcription factor Pax-5 occupies a central role in B cell differentiation and has been implicated in the development of B cell lymphoma. 15385562 Human
pax-5 b-cell lymphoma The Pax-5 isoforms are expressed in peripheral blood mononuclear cells, cancerous and non-cancerous B cell lines, as well as in primary B cell lymphoma tissue. 15385562 Human
pax-5 chronic lymphocytic leukemia (cll) Since Pax-5 and Id-2 transcription factors play an opposing role in AID regulation, we have studied the expression of Pax-5, Id-2, and prdm-1 genes in 54 chronic lymphocytic leukemia (CLL) B cells. 15561888 Human
pax-5 tumour The incidence of PIM-1, PAX-5, RhoH/TTF, and c-MYC mutations in tumour biopsy specimens from 32 HCV-infected B-cell NHL patients was analysed to determine whether the extent of aberrant SHM among these patients differed from that previously reported for H 15809970 Human
pax-5 merkel-cell carcinoma B-Cell Specific Activation Protein Encoded by the PAX-5 Gene Is Commonly Expressed in Merkel Cell Carcinoma and Small Cell Carcinomas. 15832095 Human
pax-5 small-cell carcinomas B-Cell Specific Activation Protein Encoded by the PAX-5 Gene Is Commonly Expressed in Merkel Cell Carcinoma and Small Cell Carcinomas. 15832095 Human
pax-5 b-cell lymphomas PAX-5 is a B cell specific transcription factor crucial for B cell ontogeny and has been detected in most of human B-cell lymphomas. 15832095 Human
pax-5 merkel-cell carcinoma We have encountered cases of Merkel cell carcinoma expressing PAX-5 during our routine evaluation of lymphoma. 15832095 Human
pax-5 lymphoma We have encountered cases of Merkel cell carcinoma expressing PAX-5 during our routine evaluation of lymphoma. 15832095 Human
pax-5 neuroendocrine tumors Because Merkel cell carcinoma is a small blue round cell tumor constantly in the differential diagnosis of lymphoma, we expanded our study in an effort to determine if PAX-5 is significantly expressed in neuroendocrine tumors. 15832095 Human
pax-5 merkel-cell carcinoma Because Merkel cell carcinoma is a small blue round cell tumor constantly in the differential diagnosis of lymphoma, we expanded our study in an effort to determine if PAX-5 is significantly expressed in neuroendocrine tumors. 15832095 Human
pax-5 lymphoma Because Merkel cell carcinoma is a small blue round cell tumor constantly in the differential diagnosis of lymphoma, we expanded our study in an effort to determine if PAX-5 is significantly expressed in neuroendocrine tumors. 15832095 Human
pax-5 small blue round cell tumor Because Merkel cell carcinoma is a small blue round cell tumor constantly in the differential diagnosis of lymphoma, we expanded our study in an effort to determine if PAX-5 is significantly expressed in neuroendocrine tumors. 15832095 Human
pax-5 small-cell carcinoma Based on our immunohistochemistry results using a monoclonal anti-PAX5 antibody with paraffin-embedded tissue sections, we report herein that PAX-5 was detected in 29 of 31 (93.5%) of Merkel cell carcinoma and 22 of 30 (73.3%) of small cell carcinoma, but 15832095 Human
pax-5 merkel-cell carcinoma Based on our immunohistochemistry results using a monoclonal anti-PAX5 antibody with paraffin-embedded tissue sections, we report herein that PAX-5 was detected in 29 of 31 (93.5%) of Merkel cell carcinoma and 22 of 30 (73.3%) of small cell carcinoma, but 15832095 Human
pax-5 carcinoid tumor Based on our immunohistochemistry results using a monoclonal anti-PAX5 antibody with paraffin-embedded tissue sections, we report herein that PAX-5 was detected in 29 of 31 (93.5%) of Merkel cell carcinoma and 22 of 30 (73.3%) of small cell carcinoma, but 15832095 Human
pax-5 merkel-cell carcinoma Furthermore, the staining intensity of PAX-5 in Merkel cell carcinoma was frequently comparable with that in most B-cell lymphomas. 15832095 Human
pax-5 b-cell lymphomas Furthermore, the staining intensity of PAX-5 in Merkel cell carcinoma was frequently comparable with that in most B-cell lymphomas. 15832095 Human
pax-5 neuroendocrine carcinomas We conclude that expression of PAX-5 is not confined to the B cell lineage and is frequently associated with neuroendocrine carcinomas. 15832095 Human
pax-5 tumour To determine the possible role of aberrant somatic hypermutation (ASHM) and activation-induced cytidine deaminase (AID) expression in the pathogenesis of mediastinal large B-cell lymphoma (MBL), the mutational status of genes affected by ASHM, including c 15842661 Human
pax-5 mediastinal large b-cell lymphoma To determine the possible role of aberrant somatic hypermutation (ASHM) and activation-induced cytidine deaminase (AID) expression in the pathogenesis of mediastinal large B-cell lymphoma (MBL), the mutational status of genes affected by ASHM, including c 15842661 Human
pax-5 plasmablastic lymphomas PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. 15578069 Human
pax-5 plasma cell myelomas PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. 15578069 Human
pax5 medulloblastoma Deregulated expression of PAX5 in medulloblastoma. 7777574 Human
pax5 medulloblastomas Of all nine PAX genes investigated, only PAX5 and PAX6 were consistently expressed in most medulloblastomas (70 and 78% of all cases, respectively), as were the genes EN1 (57%) and EN2 (78%). 7777574 Human
pax5 medulloblastoma PAX5 transcripts were, however, not detected in the neonatal cerebellum, indicating that this gene is deregulated in medulloblastoma. 7777574 Human
pax5 medulloblastoma In the desmoplastic variant of medulloblastoma, PAX5 expression was restricted to the reticulin-producing proliferating tumor areas containing undifferentiated cells; PAX5 was not expressed in the reticulin-free nonproliferating islands undergoing neurona 7777574 Human
pax5 pd A high-resolution analysis of a PD structure has been performed [Xu et al., Cell 80 (1995) 639-650] and the DNA-binding characteristics of members of two Pax subfamilies (Pax2, Pax5 and Pax6) have been determined. 7557441 Human
pax5 diffuse astrocytomas In primary human diffuse astrocytomas, PAX5 expression inversely correlated with p53 expression. 8521821 Human
pax5 astrocytomas PAX5 expression correlates with increasing malignancy in human astrocytomas. 9815975 Human
pax5 malignancy PAX5 expression correlates with increasing malignancy in human astrocytomas. 9815975 Human
pax5 brain tumors The expression of PAX5, which maps to chromosome 9p13, was studied in primary human brain tumors of astrocytic origin. 9815975 Human
pax5 astrocytomas Whereas murine Pax5 is not expressed in the forebrain at any stage, PAX5 expression was increased in a range of astrocytomas (WHO grades II-IV) which originated in the forebrain. 9815975 Human
pax5 malignancy We conclude that the missappropriate expression of PAX5 may aid in promoting the progression of astrocytomal malignancy. 9815975 Human
pax5 b-cell non-hodgkin's lymphoma Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma. 9722295 Human
pax5 transitional cell carcinoma of the bladder The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. 10368252 Human
pax5 malignancy The odds ratio for PAX5 expression in malignancy suggests that it increases the risk of malignancy four-fold. 10368252 Human
pax5 malignancy This is the first report of PAX5 rearrangement in a human malignancy resulting in a chimeric transcript. 11406533 Human
pax5 medulloblastomas Several Pax genes are also involved in chromosomal translocations causing malignancies in humans, and Pax5 expression is deregulated in medulloblastomas. 11477548 Human
pax5 medulloblastomas We then generated transgenic mice expressing human Pax5 under control of the Engrailed-2 promoter, which is expressed in the cerebellar external granule cell layer and in medulloblastomas. 11477548 Human
pax5 hematopoietic tumors Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. 12406913 Human
pax5 acute leukemias Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. 14676435 Human
pax5 non-hodgkin's lymphomas Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. 14676435 Human
pax5 hematologic malignancies We studied the expression of Pax5 in hematologic malignancies to evaluate the diagnostic utility as a B cell marker. 14676435 Human
pax5 mantle-cell lymphomas Pax5 was strongly expressed in most of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of 16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follicular lymphomas, and 2 Burkitt's lymphomas (100%). 14676435 Human
pax5 diffuse large b-cell lymphomas Pax5 was strongly expressed in most of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of 16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follicular lymphomas, and 2 Burkitt's lymphomas (100%). 14676435 Human
pax5 follicular lymphomas Pax5 was strongly expressed in most of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of 16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follicular lymphomas, and 2 Burkitt's lymphomas (100%). 14676435 Human
pax5 b-cell lymphomas Pax5 was strongly expressed in most of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of 16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follicular lymphomas, and 2 Burkitt's lymphomas (100%). 14676435 Human
pax5 marginal-zone b-cell lymphomas Pax5 was strongly expressed in most of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of 16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follicular lymphomas, and 2 Burkitt's lymphomas (100%). 14676435 Human
pax5 burkitt's lymphomas Pax5 was strongly expressed in most of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of 16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follicular lymphomas, and 2 Burkitt's lymphomas (100%). 14676435 Human
pax5 acute leukemias We concluded that Pax5 is very useful B cell marker in classification of lymphomas, but not of acute leukemias. 14676435 Human
pax5 lymphomas We concluded that Pax5 is very useful B cell marker in classification of lymphomas, but not of acute leukemias. 14676435 Human
pax5 leukemia The present study analyzed the expression of the following 13 TFs: AML1, CEBPA, E2A, ETS1, GATA1, GATA2, GATA3, IKAROS, IRF1, PAX5, PU1, TBET and TCF1 in 7 malignant NK-cell lines together with 5 malignant NKT-cell lines, 5 T-cell acute lymphoblastic leuk 15369140 Human
pax5 t-cell acute lymphoblastic leukemia The present study analyzed the expression of the following 13 TFs: AML1, CEBPA, E2A, ETS1, GATA1, GATA2, GATA3, IKAROS, IRF1, PAX5, PU1, TBET and TCF1 in 7 malignant NK-cell lines together with 5 malignant NKT-cell lines, 5 T-cell acute lymphoblastic leuk 15369140 Human
pax5 neuroblastoma The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. 15155532 Human
pax5 neuroblastoma Screening of neuroblastoma cell lines revealed PAX5 expression in a malignant subset of neuroblastoma cells, so-called 'N-type' cells, but not in the more benign 'S-type' neuroblastoma cells. 15155532 Human
pax5 small-cell lung cancer PAX5 expression was also detected in small cell lung cancer, an aggressive tumor of neural crest origin. 15155532 Human
pax5 tumor PAX5 expression was also detected in small cell lung cancer, an aggressive tumor of neural crest origin. 15155532 Human
pax5 small-cell lung cancer Down-regulation of PAX5 in several N-type cell lines and one small cell lung cancer cell line utilizing small interfering RNA resulted in a significant decrease in growth rate. 15155532 Human
pax5 neuroblastoma Taken together we propose PAX5 as an important factor for the maintenance of the proliferative and tumorigenic phenotype of neuroblastoma. 15155532 Human
pax5 cancer Our data, together with a recent study on the role of PAX genes in cancer suggest that PAX5 and other PAX transcription factors might be valuable targets for cancer therapy. 15155532 Human
pax5 plasmacytoma The transcription factor Pax5 activated endogenous mb-1 transcription in a plasmacytoma cell line, but could not when the promoter was methylated. 15361869 Human
pax5 nlphl RESULTS: Each of the analyzed NLPHL cases showed a different type of BCL6 rearrangement that included the t(3;22)(q27;q11) targeting immunoglobulin (IG) alpha chain locus, complex t(3;7;3;1) involving the 7p12/Ikaros gene region, t(3;9)(q27;p13) affecting 15339680 Human
pax5 multiple myeloma Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. 15195108 Human
pax5 myeloma To investigate PAX5 gene expression and its protein product, B-cell-specific activator protein (BSAP), in a subgroup of multiple myeloma characterized by CD20 expression, we studied PAX5/BSAP by immunohistochemistry in 25 cases of myeloma, all expressing 15195108 Human
pax5 multiple myeloma To investigate PAX5 gene expression and its protein product, B-cell-specific activator protein (BSAP), in a subgroup of multiple myeloma characterized by CD20 expression, we studied PAX5/BSAP by immunohistochemistry in 25 cases of myeloma, all expressing 15195108 Human
pax5 myelomas PAX5 mRNA levels correlated inversely with that of PRDM1 in both CD20-positive and CD20-negative myelomas and failed to predict the expression levels of PAX5/BSAP, suggesting that detected PAX5/BSAP likely represents remnant of earlier stage of developmen 15195108 Human
pax5 myelomas We conclude that CD20-positive myelomas expressing PAX5/BSAP can present as a diagnostic pitfall mimicking B-cell neoplasms with plasmacytoid differentiation. 15195108 Human
pax5 neoplasms We conclude that CD20-positive myelomas expressing PAX5/BSAP can present as a diagnostic pitfall mimicking B-cell neoplasms with plasmacytoid differentiation. 15195108 Human
pax5 acute leukemias PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. 15492262 Human
pax5 myelogenous leukemia PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. 15492262 Human
pax5 acute leukemias The transcription factor PAX5 plays a key role in the commitment of hematopoietic precursors to the B-cell lineage, but its expression in acute leukemias has not been thoroughly investigated. 15492262 Human
pax5 myeloid leukemias Moreover, among AMLs, PAX5 expression selectively clusters with t(8;21), allowing its immunohistochemical recognition in a proportion of cases, and likely explaining a peculiar biological feature of this subset of myeloid leukemias, i.e. the aberrant expr 15492262 Human
pax5 myeloid sarcoma Immunohistochemical studies are extremely helpful for recognizing isolated myeloid sarcoma. 15628906 Human
pax5 leukemias Through the use of novel biological network analyses, essential regulators of early B cell development, PAX5 and EBF, were shown to be associated with a clear B-lineage commitment in lymphoblastic t(11q23)/MLL leukemias. 15815718 Human
pax5 b-cell lymphomas Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation Lack PAX5 Gene Rearrangements. 16049306 Human
pax5 b-cell lymphomas Thus, we analyzed a series of low-grade B-cell lymphomas for PAX5 gene rearrangements. 16049306 Human
pax5 b-cell lymphomas All cases failed to demonstrate a PAX5 translocation, indicating that t(9;14)(p13;q32) and other PAX5 translocations are uncommon events in low-grade B-cell lymphomas with plasmacytic differentiation. 16049306 Human
pax5 lymphoplasmacytic lymphoma In contrast to initial observations describing this translocation in lymphoplasmacytic lymphoma (LPL) and LPL-derived large B-cell lymphoma, our data showed a wide morphologic and clinical spectrum associated with the PAX5/IGH rearrangement, pointing to a 15942942 Human
pax5 large b-cell lymphoma In contrast to initial observations describing this translocation in lymphoplasmacytic lymphoma (LPL) and LPL-derived large B-cell lymphoma, our data showed a wide morphologic and clinical spectrum associated with the PAX5/IGH rearrangement, pointing to a 15942942 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.